Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

No, nothing is different. They have been saying they have approval for a new product, in a new market, every 6 months. There are plenty of Companies selling product in Germany, and plenty losing money: https://mjbizdaily.com/germanys-cannabis-market-is-evolving-but-elections-loom/

"The price of cannabis in Germany dropped to an all-time low in the fourth quarter of 2024 - In October and November, some medical cannabis strains sold for as low as 3.99 euros ($4.12) per gram."

Build it and they will come, does not work, unfortunately. They will have almost 0% chance competing with a me-too product in Germany, and they have no actual pharma products with IP. It's musical chairs, spending edition, until they finally run out of money.